Sovereign's Capital Management’s Amicus Therapeutics FOLD Stock Holding History

Sovereign's Capital Management’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-784,942	Closed	-$11.2M	–	80
2025 Q4	$11.2M	Sell	784,942 -49,487	-6%	-$486K	6.78%	1
2025 Q3	$6.58M	Buy	834,429 +478,820	+135%	+$3.41M	3.57%	2
2025 Q2	$2.04M	Buy	355,609 +45,248	+15%	+$292K	1.09%	35
2025 Q1	$2.53M	Buy	310,361 +12,531	+4%	+$116K	1.51%	28
2024 Q4	$2.81M	Buy	+297,830	New	+$3.1M	1.79%	23

Other funds holding FOLD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Sovereign's Capital Management's FOLD Position: Q1 2026 in Review

Sovereign's Capital Management sold out of Amicus Therapeutics (FOLD) in Q1 2026, closing a stake of 784,942 shares — an estimated $11.2M sold.

Sovereign's Capital Management first reported a position in FOLD in Q4 2024 and held it in 5 quarters. The position peaked at $11.2M in Q4 2025. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

Sovereign's Capital Management reported no remaining Amicus Therapeutics position as of Q1 2026 after selling out during the quarter.
Sovereign's Capital Management sold 784,942 Amicus Therapeutics shares in Q1 2026, an estimated $11.2M.
Sovereign's Capital Management first reported a position in Amicus Therapeutics in Q4 2024 and held it in 5 quarters.
Sovereign's Capital Management's Amicus Therapeutics position peaked at $11.2M in Q4 2025.
298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Sovereign's Capital Management's 13F filing for Q1 2026, filed 15 May 2026.